spacer
home > epc > autumn 2002 > comparison of the regulatory ames test with the sos/umu assay as part of lead optimisation screening
PUBLICATIONS
European Pharmaceutical Contractor

Comparison of the Regulatory Ames Test with the SOS/umu Assay as Part of Lead Optimisation Screening

In our experience, regulatory genetic toxicology testing consistently produces 20-25 per cent in vitro positive results each year (Ames, cytogenetics and mammalian cell mutation). For the customers concerned, this means, at best, significant delays while further testing is carried out using more precious compound. At worst the pharmaceutical will fail further down the development pipeline.

Either way a positive genetic toxicology result leads to considerable cost and delay. The problem is even greater when using the 'fast-track, early into human' approach preferred by some customers when the toxicology study package has been 'compressed' to save time. A significant failure will bring down a whole programme. To aid screening for potential genotoxins, we assessed the performance of the SOS/umu assay, carried out in microwell plates, when compared to the regulatory Ames test performed to OECD guidelines.

Materials and Methods

The SOS/umu assay, performed in microwell plates, has the advantage of being sensitive to a wide range of genotoxins and has been shown to correlate well with the Ames test.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Jon Kitching, Department of Experimental Biology at Huntingdon Life Sciences

Jon Kitching heads up the Molecular Toxicology Group within the Experimental Biology Department at Huntingdon Life Sciences. With a dual honours degree in Biochemistry and Microbiology, Jon previously worked in genetic toxicology for 12 years.

spacer
Jon Kitching
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Senior Vice President Dr. David Daniel Honored in PharmaVOICE 100

Philadelphia, PA August 1, 2019: Signant Health (formerly CRF Health and Bracket) today announces that its Senior Vice President, Dr. David Daniel, has been selected by PharmaVOICE as one of the top 100 most inspiring people within the life sciences sector. Dr. Daniel was selected from a large cross section of established professionals in the life sciences industry for his passion to continually improve the way in which science, technology and service interact. This honor swiftly follows another recent mark of distinction for Dr. Daniel, having been co-awarded the 2019 ISCDD Scientific Leadership Award.
More info >>

White Papers

Autoinjector testing made safe efficient and flexible

ZwickRoell

The autoinjector market is one of the fastest growing markets across almost all pharmaceutical applications. Studies expect a global market volume of approximately USD 2.5 billion by 2020, with pre-filled autoinjectors representing the largest market segment. There are a variety of tests that can be performed on autoinjectors, and these are well-demonstrated by the Zwick product portfolio. The Ulm-based company and specialist in testing systems offers a variety of testing systems that are already being successfully used by multiple pharmaceutical companies.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement